Quantcast

Latest Rituximab Stories

2014-02-03 23:02:17

Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Philadelphia, PA (PRWEB) February 03, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1912, a randomized phase III clinical trial to evaluate the ability of the combination of ibrutinib and rituximab to prolong progression-free survival in previously...

2014-01-31 10:46:34

In patients with a frequently-relapsing form of kidney disease, relapses decreased approximately five-fold for at least one year after patients took a single dose of rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis. The findings, which will appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), suggest that this drug may provide considerable benefits for patients. For most...

2014-01-24 12:23:26

SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera(®) (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)...

2014-01-24 11:25:34

Results on test of Idelalisib suggest CLL may be treated without toxic chemotherapy Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team. Their findings on the therapy for chronic lymphocytic leukemia (CLL), reported in the Jan. 22 issue of the New England Journal of Medicine, suggest that patients may be able to avoid having to take debilitating...

2014-01-13 08:30:25

SHANGHAI, Jan. 13, 2014 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. Dr. Reff brings over 30 years of research and development experience in the biopharmaceutical industry. Dr. Reff's appointment further strengthens the world-class technical capabilities of ChemPartner's Biologics Division and offers Pharmaceutical and Biotechnology companies from around the world first-rate strategic and...

2014-01-06 04:21:41

- PIXUVRI Deemed Cost Effective for Patients with Multiply Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - SEATTLE, Jan. 6, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related